MME Monika BADER

Rhumatologue

📍 CORBEIL ESSONNES (91)LibéralRPPS 10001480861

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR MONIKA BADER
GROUPE MEDICAL DES TARTERETS 9 RUE HENRI MATISSE, 91100 CORBEIL ESSONNES
Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Lrp5 functions in bone to regulate bone mass

Nature medicine · 2011

📚 358 citations🎯 RCR 9.74Top 3% NIH🔓 Open Access

The role of kinin B1 receptor and the effect of angiotensin I-converting enzyme inhibition on acute gout attacks in rodents

Annals of the rheumatic diseases · 2016

📚 35 citations🎯 RCR 1.43

Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014

📚 32 citations🎯 RCR 1.15

Lire l'abstract Crossref ↓

ABSTRACT It has recently been suggested that the low-density lipoprotein receptor-related protein 5 (LRP5) regulates bone mass by suppressing secretion of serotonin from duodenal enterochromaffin cells. In mice with targeted expression of a high bone mass–causing (HBM-causing) LRP5 mutation and in humans with HBM LRP5 mutations, circulating serotonin levels have been reported to be lower than in controls whereas individuals with loss-of-function mutations in LRP5 have high blood serotonin. In contrast, others have reported that conditionally activating a knock-in allele of an HBM-causing LRP5 mutation in several tissues, or genetic deletion of LRP5 in mice has no effect on serum serotonin levels. To further explore the possible association between HBM-causing LRP5 mutations and circulating serotonin, levels of the hormone were measured in the platelet poor plasma (PPP), serum, and platelet pellet (PP) of 16 affected individuals from 2 kindreds with HBM-causing LRP5 mutations (G171V and N198S) and 16 age-matched controls. When analyzed by HPLC, there were no differences in levels of serotonin in PPP and PP between affected individuals and age-matched controls. Similarly, when analyzed by ELISA, there were no differences in PPP or PP between these two groups. By ELISA, serum levels of serotonin were higher in the affected individuals when compared to age-matched controls. A subgroup analysis of only the G171V subjects (n = 14) demonstrated that there were no differences in PPP and PP serotonin between affected individuals and controls when analyzed by HPLC. PP serotonin was lower in the affected individuals when measured by ELISA but serum serotonin levels were not different. We conclude that there is no change in PPP serotonin in individuals with HBM-causing mutations in LRP5. © 2014 American Society for Bone and Mineral Research.

Cookies & analyse de trafic

MME Monika BADER

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (11) — classées par pathologie

Transversal7

Case report / série1

csDMARDs1

Économie santé1

Goutte1

Revue générale1

Partager cette fiche